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Abstract
Background: Baseline serum creatinine (SCr) level is frequently not measured in clinical practice. The aim of this
study was to investigate the effect of various methods of baseline SCr determination measurement on accuracy of
acute kidney injury (AKI) diagnosis in critically ill patients.
Methods: This was a retrospective cohort study. All adult intensive care unit (ICU) patients admitted at a tertiary
referral hospital from January 1, 2011 through December 31, 2011, with at least one measured SCr value during ICU
stay, were included in this study. The baseline SCr was considered either an admission SCr (SCrADM) or an estimated
SCr, using MDRD formula, based on an assumed glomerular filtration rate (GFR) of 75 ml/min/1.73 m2 (SCrGFR-75).
Determination of AKI was based on the KDIGO SCr criterion. Propensity score to predict the likelihood of missing
SCr was used to generate a simulated cohort of 3566 patients with baseline outpatient SCr, who had similar
characteristics with patients whose outpatient SCr was not available.
Results: Of 7772 patients, 3504 (45.1 %) did not have baseline outpatient SCr. Among patients without baseline
outpatient SCr, AKI was detected in 571 (16.3 %) using the SCrADM and 997 (28.4 %) using SCrGFR-75 (p < .001).
Compared with non-AKI patients, patients who met AKI only by SCrADM, but not SCrGFR-75, were significantly associated
with 60-day mortality (OR 2.90; 95 % CI 1.66–4.87), whereas patients who met AKI only by SCrGFR-75, but not SCrADM,
had a non-significant increase in 60-day mortality risk (OR 1.33; 95 % CI 0.94–1.88). In a simulated cohort of patients
with baseline outpatient SCr, SCrGFR-75 yielded a higher sensitivity (77.2 vs. 50.5 %) and lower specificity (87.8 vs. 94.8 %)
for the AKI diagnosis in comparison with SCrADM.
Conclusions: When baseline outpatient SCr was not available, using SCrGFR-75 as surrogate for baseline SCr was found
to be more sensitive but less specific for AKI diagnosis compared with using SCrADM. This resulted in higher incidence
of AKI with larger likelihood of false-positive cases.
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Background
Acute kidney injury (AKI) is commonly associated with
high morbidity and mortality in critically ill patients [1–4].
Even a modest degree of AKI is associated with mortality,
morbidity, and increased healthcare cost [5–10]. The Kid-
ney Disease: Improving Global Outcomes (KDIGO) criteria
was developed and validated to standardize the diagnosis
and severity of AKI based on absolute or relative increases
from baseline serum creatinine (SCr) levels, as well as pro-
gressive oliguria [11]. Thus, determination of baseline SCr
is important to diagnose and classify AKI [12, 13].
Despite development of the KDIGO criteria, classifica-
tion of AKI remains challenging, as baseline outpatient
SCr measurement—a marker of kidney function prior to
the critical illness—is often unavailable [14]. In this case,
the Acute Dialysis Quality Initiative (ADQI) has recom-
mended backward calculation of baseline SCr using the
Modification of Diet in Renal Disease (MDRD) formula,
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this formula assumes an estimated glomerular filtration
rate (eGFR) value of 75 ml/min/1.73 m2 (SCrGFR-75) for
all patients with missing data [15]. However, backward
calculation can lead to misclassification of AKI, particu-
larly in the early stages of this syndrome [16, 17].
The European Renal Best Practice (ERBP) recently pro-
posed using the first documented SCr value on hospital
admission (SCrADM)—rather than SCrGFR-75—as the base-
line SCr when baseline outpatient SCr measurements are
missing [18]. However, the use of SCrADM as the baseline
SCr can be inaccurate in patients with community-
acquired AKI, as the SCr may have already increased prior
to hospitalization [19, 20]. Additionally, the predictive per-
formance of these two methods on mortality has not been
well studied [18].
The primary objective of this study was to compare
the incidence and staging of AKI according to SCr cri-
teria using SCrGFR-75 versus SCrADM. The secondary ob-
jective of this study was to determine the accuracy of
AKI diagnosis in critically ill patients using SCr estima-
tion, based on assumed GFR and SCrADM, compared to
the reference standard of SCr measurement.
Methods
Study Population
This is a single-center retrospective study conducted at
a tertiary referral hospital. We studied all adult patients
(age ≥18 years) admitted to the ICU at Mayo Clinic in
Rochester, MN, from January 1, 2011 through December
31, 2011. We included patients who had at least one SCr
measured during the ICU admission. Patients with a his-
tory of stage 5 chronic kidney disease (CKD) or end-stage
renal disease (ESRD), patients who received any dialysis
modalities within 14 days prior to the ICU admission, and
those who did not provide research authorization were ex-
cluded from the study. Stage 5 CKD and ESRD were
identified based on ICD-9 code assignment (Additional
file 1: Table S1) or baseline outpatient SCr-calculated
eGFR of <15 ml/min/1.73 m2. For patients with multiple
ICU admissions, only the first ICU admission during the
study period was included in the analysis. This study was
approved by the Mayo Clinic institutional review board.
We divided eligible patients into two groups, based on
the availability of outpatient SCr between 365 and 7 days
prior to hospital admission (Fig. 1). One group included
patients without baseline outpatient SCr (n = 3504). This
is the cohort of patients for whom the use of surrogates
for baseline SCr was actually applied. This cohort was
used to compare the incidence and outcomes of AKI
using SCrGFR-75 versus SCrADM in order to represent the
real-world finding. The second group included patients
with baseline outpatient SCr (n = 4268).
Simulated cohort
AKI diagnosis based on outpatient SCr baseline can be
used as a reference standard to assess the sensitivity and
specificity of AKI diagnosis using various surrogate esti-
mates. However, due to significant differences in clinical
characteristics between patients with and without out-
patient SCr (Table 1), the finding in the cohort of pa-
tients with outpatient SCr might not be generalizable to
patients without outpatient SCr. Therefore, we devel-
oped a propensity score model in which the outcome
was whether baseline SCr was missing (n = 3504) or not
Fig. 1 Study inclusion and exclusion flow diagram
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(n = 4268) to predict the likelihood of missing baseline
SCr. The propensity model included age, race, diabetes
mellitus, hypertension, coronary artery disease, stroke, per-
ipheral vascular disease, congestive heart failure, and APA-
CHE III at ICU admission as covariates. We applied this
model to the group of patients with baseline outpatient
SCr and then selected patients with a propensity score of
≥0.354 (post-hoc cut-off) to generate a study cohort of
patients with similar characteristics to patients whose
baseline SCr was not available, while preserving known
baseline SCr (n = 3566). We used this simulated cohort to
analyze the sensitivity and specificity of AKI diagnosis
based on different surrogates. AKI diagnosis based on out-
patient SCr was used as the reference standard.
Data collection
Clinical characteristics, demographic information, and la-
boratory data were collected using manual and automated
retrieval from the institutional electronic medical records.
We utilized data from the Mayo Clinic Life Science System
(MCLSS) and the Multidisciplinary Epidemiology and
Translational Research in Intensive Care (METRIC) data-
base. The MCLSS database contained demographic char-
acteristics, clinical data, hospital admission information,
diagnosis codes, procedure codes, laboratory test results,
and flowsheet data of both in- and outpatients at our insti-
tution [21]. The METRIC database contained ICU admis-
sion information, pertinent vital signs, fluid input/output,
and medication administration record data of all patients
admitted in ICU at our institution [22]. Data variables
collected included age, sex, race, known comorbidities at
hospital admission, ICU type, severity of illness at ICU ad-
mission, ICU length of stay, and ICU discharge status. SCr
measurements were collected for each eligible patient up
to one year prior to ICU admission. The baseline out-
patient SCr was defined as the most recent outpatient SCr
measured between 365 and 7 days prior to the hospital ad-
mission. The eGFR was derived using the MDRD equation,
with CKD being defined as a calculated eGFR of <60 ml/
min/1.73 m2. We identified comorbidities from clinical
notes in electronic medical record using a validated elec-
tronic note search strategy [21]. The severity of illness at
ICU admission was evaluated using the Acute Physiology
and Chronic Health Evaluation (APACHE) III score [23].
AKI diagnosis and classification
We identified and staged AKI based solely on the SCr
criterion of the KDIGO definition [11]. AKI was defined
Table 1 Clinical characteristics and outcomes of eligible critically ill patients admitted to the ICU during the study period
Characteristics Outpatient SCr not available Outpatient SCr available p* Simulated Cohorta p*
N 3,504 4,268 3566
Age, year 62 ± 18 65 ± 16 <0.001 63 ± 16 0.05
Male sex 2013 (57) 2508 (59) 0.24 2033 (57) 0.71
White 3246 (93) 4039 (95) <0.001 3347 (94) 0.10
Baseline creatinine, mg/dL
- Admission SCr 1.1 ± 0.9 1.1 ± 0.8 0.55 1.1 ± 0.8 0.10
- Single imputation of GFR 75 ml/min/1.73 m2 1.0 ± 0.1 1.0 ± 0.1 0.20 1.0 ± 0.1 0.06
- Baseline outpatient SCr - 1.1 ± 0.4 - 1.1 ± 0.4 -
Comorbidities
- Diabetes Mellitus 723 (21) 1114 (26) <0.001 730 (20) 0.87
- Hypertension 1836 (52) 2653 (62) <0.001 2004 (56) 0.04
- Coronary artery disease 809 (23) 1376 (32) <0.001 793 (22) 0.39
- Stroke 272 (8) 472 (11) <0.001 240 (7) 0.12
- Peripheral vascular disease 120 (3) 258 (6) <0.001 60 (2) 0.10
- Congestive heart failure 311 (9) 588(14) <0.001 252 (7) 0.07
Medical ICU type 1733 (49) 2036 (48) 0.12 1689 (47) 0.08
APACHE III 44 ± 22 50 ± 20 <0.001 46 ± 18 0.06
Renal replacement therapy use in ICU 89 (3) 109 (3) 0.97 78 (2) 0.33
ICU mortality 102 (3) 136 (3) 0.48 94 (3) 0.48
60-day mortality 298 (9) 468 (11) <0.001 338 (9) 0.15
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, GFR glomerular filtration rate, ICU intensive care unit, IQR interquartile range SCr serum
creatinine, SOFA sequential organ failure assessment
*Compared with patients without baseline outpatient SCr
aSimulated cohort was a subset of patients with available baseline outpatient SCr with propensity score to predict the likelihood of missing baseline SCr of ≥ 0.354
Continuous data are presented as mean ± SD, categorical data are presented as N (%), if not indicated
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as an increase in SCr in the ICU of ≥0.3 mg/dL or rela-
tive change of ≥50 % from the baseline. The baseline
SCr was calculated using two different methods; 1) the
first SCr available during hospital admission (SCrADM),
and 2) an estimated SCr using the MDRD formula,
based on an assumed GFR of 75 ml/min/1.73 m2
(SCrGFR-75, as recommended by the ADQI working






186  age‐0:203   0:742 for womenð Þ
 1:21 for blackð ÞÞ‐0:887
Clinical outcomes
The primary outcome was all-cause mortality at 60 days
following ICU admission. We reviewed patient vital sta-
tistics by reviewing the patient registration and elec-
tronic medical records. In patients whose vital status at
60 days after ICU admission was unknown, the Social
Security Death Index was used [24].
Statistical analysis
Continuous variables were reported as mean with stand-
ard deviation (SD) or median with interquartile range
(IQR), as appropriate. All categorical variables were re-
ported as counts with percentages. The difference in the
AKI diagnosis using SCrADM andSCrGFR-75 was assessed
using McNemar’s test. The agreement of AKI diagnosis
and staging, based on SCrADM and SCrGFR-75, was assessed
using Cohen’s weighted kappa coefficient with linear
weight between AKI stages. According to the results of
AKI diagnosis, based on SCrADM and SCrGFR-75, we classi-
fied patients into 4 groups: (1) patients who had AKI re-
gardless of baseline SCr calculation method, (2) patients
who had AKI based only on SCrADM, (3) patients who had
AKI only based on SCrGFR-75, and (4) patients who did not
have AKI, regardless of baseline SCr determination meth-
odology. We adjusted the odds ratio (OR) for age, ICU
type, and APACHE III scores to assess 60-day mortality
for the first three groups, using the fourth group as the
reference group. The association between AKI stages and
60-day mortality was assessed using a logistic regression
analysis. The predictive performance of the SCr criterion,
using SCrADM and SCrGFR-75, for 60-day mortality was
assessed by C-statistics, after which we compared their
performances using Delong’s test. We calculated net re-
classification improvement to evaluate how using SCrGFR-
75 as baseline renal function for AKI diagnosis changed
risk classification for 60-day mortality.
Sensitivities and specificities were compared using
McNemar’s test. To determine the optimal GFR used for
SCr estimation, we estimated based on an assumed GFR
with an increment of 5 ml/min/1.73 m2, ranging from
30 to 120 ml/min/1.73 m2. The sensitivity and specificity
of AKI diagnosis, according to the estimated SCr of each
assumed GFR, was calculated using AKI diagnosis ac-
cording to the baseline outpatient SCr as a reference
standard. The Youden index, which yielded the highest
sum of sensitivity and specificity, was used to identify
the optimal GFR used for SCr estimation. The subgroup
analyses, based on sex, age, and the presence of abnor-
mal renal function at presentation, were performed to
investigate the optimal GFR used in each subgroup. A
two-sided p value of less than 0.05 was considered statis-
tically significant. All analyses were performed using
JMP statistical software (version 10.0, SAS, Cary, NC).
Results
During the study period, 9277 critically ill patients were
admitted to the ICU. Of these, 1,505 were excluded: 498
did not provide authorization to use their data for re-
search, 194 aged < 18 years, and 386 had no measured
SCr values in ICU, 427 had ESRD, or received dialysis
within 14 days prior to ICU admission. Thus, 7772 pa-
tients were included in this study. The baseline out-
patient SCr was not available for 3504 of these patients
(45.1 %). The clinical characteristics of these patients
upon ICU admission and their outcomes are summarized
in Table 1. Patients who had available baseline outpatient
SCr were older, Caucasian, had more known comorbidi-
ties, and had higher APACHE and SOFA scores at ICU
admission. Patients in the simulated cohort had similar
characteristics to patients without baseline outpatient SCr.
AKI diagnosis and staging using the admission and
estimated SCr
Among patients without baseline outpatient SCr, using
SCrADM, AKI occurred in 571 patients (16.3 %), with
12.1 % in stage 1, 2.3 % in stage 2, and 1.9 % in stage 3.
UsingSCrGFR-75, AKI occurred in 997 patients (28.4 %),
with 15.6 % in stage 1, 7.4 % in stage 2 and 5.5 % in
stage 3. SCrGFR-75 classified more patients into AKI than
SCrADM (p < .001) (Table 2).
The percentage agreement for AKI diagnosis using
SCrADM and SCrGFR-75 for baseline SCr estimation was
79.5 % with a kappa of 0.42 (95 % CI, 0.39–0.46). SCrADM
and SCrGFR-75 as baseline SCr agreed in 425 AKI cases and
2361 non-AKI cases. Using SCrADM and SCrGFR-75 resulted
in a discrepancy in AKI diagnoses of 718 cases (20.5 %).
146 patients met the AKI diagnosis by only SCrADM and
572 met the AKI diagnosis using only SCrGFR-75. The per-
centage agreement for AKI staging, using both SCrADM
and SCrGFR-75, was 74.4 % with a kappa of 0.39 (95 % CI,
0.36–0.42). Ninety six percent of AKI based only by
SCrGFR-75 but not SCrADM occurred within 24 hours of
ICU admission.
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Risk for 60-day mortality
Of the total cohort, 8.5 % (N = 298) died within 60 days of
ICU admission. The 60-day mortality rates after ICU ad-
mission for AKI stages by using SCrADM and SCrGFR-75
are shown in Fig. 2. Compared with patients without AKI,
patients who met AKI regardless of baseline SCr meth-
odology, and patients who met AKI only by SCrADM,
but not SCrGFR-75, were significantly associated with in-
creased 60-day mortality (OR = 3.66 [95 % CI, 2.65–5.04]
and OR = 2.90 [95 % CI, 1.66–4.87]). However, patients
who met AKI only by SCrGFR-75, but not SCrADM, had a
non-significant increase in 60-day mortality risk (OR 1.33;
95 % CI 0.94–1.88) (Table 3 and Fig. 3). Calculating the per-
formance for prediction of 60-day mortality, the C-statistic
for AKI stages using SCrADM and SCrGFR-75 as baseline SCr
were 0.64 and 0.68 respectively (p = .001). Using SCrGFR-75
for AKI diagnosis improved risk classification for 60-day
mortality with net reclassification improvement of 4.7 %.
Sensitivity and specificity for AKI diagnosis
In the simulated cohort of patients with available baseline
outpatient SCr, the mean baseline SCr (SD) was 1.1 ±
0.4 mg/dL. Of these patients, 20.7 % (n = 738) experienced
AKI using known baseline outpatient SCr, 14.6 % (n = 520)
using SCrADM, and 25.7 % (n = 915) using SCrGFR-75. Appli-
cation of SCrGFR-75 as baseline SCr yielded a sensitivity of
77.2 % and specificity of 87.8 % for the AKI diagnosis.
Using SCrADM as baseline SCr yielded a sensitivity of
50.5 % and specificity of 94.8 %. Overall, SCrGFR-75 was
more sensitive (p < .001), whereas SCrADM was found to be
more specific (p < .001). The application of either SCrGFR-75
or SCrADM, compared to AKI diagnosis and staging based
on baseline outpatient SCr, resulted in bi-directional mis-
classification of AKI (Additional file 1: Table S2).
Optimal GFR used for SCr estimation
The sensitivity and specificity of AKI diagnosis, when
using different assumed GFR for SCr estimation, were
shown in Table 4. The most optimal GFR with the highest
sum of sensitivity and specificity was 85 ml/min/1.73 m2,
yielding a sensitivity of 85.2 % and a specificity of 83.0 %.
The sensitivity and specificity in different subgroups based
on sex, age, and the presence of abnormal renal function
at presentation are summarized in Additional file 1: Table
S3 with the most optimal GFR for SCr estimation indi-
cated. The application of SCrADM for AKI diagnosis in
patients with abnormal renal function at presentation re-
sulted in significantly lower sensitivity (41.7 vs. 65 %), but
similar specificity (92.7 vs. 95.3 %), for AKI diagnosis.
Discussion
We conducted a retrospective cohort study to assess the ef-
fect of using different baseline SCr methods, SCrGFR-75 and
SCrADM, on the incidence of AKI as well as prognostication
Table 2 AKI diagnoses and staging using admission SCr and




AKI stage (SCrADM) Total N
(%)0 1 2 3
0 2361 (67.4) 133 (3.8) 13 (0.4) 0 (0) 2507 (71.6)
1 356 (10.2) 160 (4.6) 28 (0.8) 2 (0.1) 546 (15.6)
2 134 (3.8) 85 (2.4) 31 (0.9) 10 (0.3) 260 (7.4)
3 82 (2.3) 45 (1.3) 9 (0.3) 55 (1.6) 191 (5.5)
Total, N (%) 2933 (83.7) 423 (12.1) 81 (2.3) 67 (1.9) 3504 (100)
Kappa = 0.42 (95 % CI 0.39-0.46) and percentage agreement = 79.5 % for
AKI diagnosis,
Kappa = 0.39 (95 % CI 0.36-0.42) and percentage agreement = 74.4%for
AKI staging
Abbreviation: AKI, acute kidney injury; SCrADM, the admission serum creatinine;
SCrGFR-75, an estimated serum creatinine based on an assumed GFR
of 75 ml/min/1.73 m2
Fig. 2 60-day mortality risk stratified by AKI stage in patients without baseline outpatient SCr
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performance of the KDIGO definition. We demonstrated
that using SCrGFR-75 as a baseline SCr for AKI diagnosis
was associated with the larger number of classified AKI
cases. However, using SCrGFR-75 resulted in the misclassifi-
cation of non-AKI cases into AKI, as AKI cases only by
SCrGFR-75, but not SCrADM, had a no significant increase in
60-day mortality risk. This finding is consistent with
SCrGFR-75 as a more sensitive and SCrADM as a more spe-
cific surrogate for AKI diagnosis when compared with out-
patient SCr as the reference standard.
Ideally, outpatient SCr values, which are reflective of pa-
tient pre-morbid kidney function, should be used as the
baseline SCr for AKI diagnosis [25]. However, the lack of
baseline outpatient SCr level is a common problem en-
countered in clinical practice [25, 26]. Following the ADQI
statement, the use of SCrGFR-75 as a baseline SCr has been
shown to lead to misclassification of AKI in ICU patients
[16, 17] and following cardiac surgery [27]. The European
Renal Best Practice (ERBP) has recommended the use of
SCrADM, rather than SCrGFR-75, when baseline outpatient
SCr measurements are not available [18]. In our study, we
demonstrated that using either SCrGFR-75 or SCrADM led to
misclassification of AKI diagnosis and staging. Use of
SCrGFR-75 has been shown to inflate AKI incidence, whereas
use of SCrADM underestimates AKI incidence [14, 16, 17].
The inflation of AKI diagnosis bySCrGFR-75as surrogates
for baseline kidney function was due to inaccurate base-
line SCr estimation in patients with chronic kidney disease
[14, 28]. In contrast, the underestimation of AKI diagnosis
when using SCrADM was due to the under-diagnosis of
community-acquired AKI [14]. We found most of AKI
cases missed by SCrADM occurred within the first 24 hours
of ICU admission.
The analysis in a simulated cohort of patients with base-
line outpatient SCr showed the higher sensitivity and lower
specificity of AKI diagnosis bySCrGFR-75 in comparison
with SCrADM. The decision to use SCrGFR-75 or SCrADM for
AKI diagnosis and classification depends on the purpose of
the AKI definition. In clinical practice, AKI prevention and
prompt treatment might improve patient outcomes. Thus,
for risk stratification purposes in clinical practice, we en-
courage the use of SCrGFR-75 for AKI diagnosis, as it can
conceivably identify more AKI cases. Conversely, for re-
search studies that enroll patients with AKI for invasive
tests or treatments, using SCrADM may be more suited, as
it would be more likely to enroll patients who are going to
benefit from the intervention.
The use of estimated SCr by back-calculation with the
MDRD formula can allow investigators or clinicians to be
more flexible regarding the sensitivity and specificity of
Table 3 60-day mortality risk based on the AKI diagnosis using
admission and GFR-estimated SCr in patients without baseline
outpatient SCr (n = 3504)
N 60-day mortality,
n (%) aOR (95 % CI)
No AKI-SCrADM AKI-SCrADM
No AKI- SCrGFR-75 2361 146
4.5 % 13.7 %
1 (ref) 2.90 (1.66-4.87)
AKI- SCrGFR-75 572 425
12.1 % 24.0 %
1.33 (0.94-1.88) 3.66 (2.65-5.04)
Abbreviation: AKI acute kidney injury, CI confidence interval, SCrADM the
admission serum creatinine, SCrGFR-75 an estimated serum creatinine based on
an assumed GFR of 75 ml/min/1.73 m2
aadjusted for age, APACHE III score and ICU type
Fig. 3 Odds ratio for 60-day mortality in patients with or without acute kidney injury using admission SCr and GFR-estimated SCr as baseline
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the AKI definition. As shown in Table 4 and Additional
file 1: Table S3, when using different assumed GFR for
SCr estimation, it provides different levels of sensitivity
and specificity that we may individualize in each patient in
different encounters. Since GFR decreases with age, the
use of SCrGFR-75 might result in over-AKI classification in
the elderly [29], therefore use of a different assumed GFR
for SCr estimation could be considered in different age
groups. For example, using SCrGFR-70 in elderly but
SCrGFR-100 in younger adult would yield the highest sum
of sensitivity and specificity. In addition, abnormal renal
function at presentation may be due to pre-existing
chronic kidney disease or due to acute elevation of SCr
from community-acquired acute kidney injury. Therefore,
estimated SCr based on lower assumed GFR might be
more suitable for patients without baseline outpatient SCr,
who present initially with an abnormal SCr. In contrast,
using SCrADM in patients with abnormal renal function
based on initial SCr value in hospital would result in lower
sensitivity in the diagnosis of AKI.
This study has several limitations. (1) This is a single-
center retrospective study. (2) We did not include the urine
output criterion for AKI diagnosis since an indwelling
urinary catheter was not used to obtain accurate hourly
urine output data for all critically ill patients. (3) Our study
compared only two common surrogates for baseline SCr
and did not include other advanced methods to estimate
the baseline SCr. For example, Siew and colleagues recently
demonstrated that a multiple imputation method can im-
prove accuracy in estimating missing baseline SCr and
reduce misclassification of AKI [30]. However, the use of
this technique in clinical practice is limited and still re-
quires further validation. A multi-center prospective study
is ultimately required to address some of these limitations.
Conclusion
When baseline outpatient SCr was not available, using
SCrGFR-75 as a surrogate for baseline SCr was found to
be more sensitive but less specific for AKI diagnosis
compared to SCrADM. This resulted in higher incidence
of AKI with larger likelihood of false-positive cases.
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diagnosis using an estimated SCr, based on various assumed GFR in
subgroups of patients (DOCX 28 kb)
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